WO2023073457A1

WO2023073457A1 - A topical pain-relief medicine for relieving headache

Info

Publication number: WO2023073457A1
Application number: PCT/IB2022/059376
Authority: WO
Inventors: Seyed Mohammad MOUSAVI MIRZAEI
Original assignee: Mousavi Mirzaei Seyed Mohammad
Priority date: 2021-10-30
Filing date: 2022-10-01
Publication date: 2023-05-04

Abstract

Disclosed herein is a topical pain-relief medicine. The topical pain-relief medicine includes an aqueous mixture, a steroid compound powder, and a nonsteroidal anti-inflammatory drug powder dissolved in a hydrophobic solvent. The aqueous mixture includes a tricyclic antidepressant compound powder and an anticholinergic compound powder dissolved in water. The nonsteroidal anti-inflammatory drug powder is dissolved in the at least a hydrophobic solvent. The aqueous mixture, the steroid compound powder, and the nonsteroidal anti-inflammatory drug powder dissolved in the hydrophobic solvent are mixed together to form a homogenous ointment or lotion.

Description

A TOPICAL PAIN-RELIEF MEDICINE FOR RELIEVING HEADACHE

TECHNICAL FIELD

[0001] The present disclosure generally relates to a topical medicine for relieving pain, and more particularly, relates to an ointment or a lotion for relieving headache.

BACKGROUND ART

[0002] Pain is a mechanism to alarm for body safety. Sensory neurons transfer signals from an injured part through spinal cord to brain. Some people may suffer from chronic pains which can decrease quality of life. Different strategies are used to decrease or even eliminate pains. These strategies include using pain medicines, physical therapies, for example, heat or cold packs, massage, hydrotherapy, and exercise, psychological therapies, for example, cognitive behavioral therapy, relaxation techniques, and meditation. Pain medicines are one of the most applicable methods to remedy pain due to high effectiveness for relieving pain in a short period of time. Pain medicines can be in form of tablet, lotion, cream, ointment, syrup, ampoule, etc. [0003] Different drugs are used as pain -relief compounds in pain medicines. The pain-relief compound includes nonsteroidal anti-inflammatory drugs, corticosteroids, tricyclic antidepressant compounds, etc.

[0004] Headaches are the most common pain that each person may experience during his life. The pain may be irritating which therefore requires medical treatment. The pain comes from signals between your brain, blood vessels, and nearby nerves in chronic headaches such as migraine.

[0005] Different strategies were applied in the prior art to relieve headaches. Ron L. Hale et al. presented a patent on “MEATHODS FOR TREATING HEADACHES WITH LOXAPINE” (US 8,288,372 B2). Ron L. Hale et al. decreased headaches by using loxapine or amoxapine systemically by inhalation. Franke Hanshermann et al. presented a patent on “TRANSDERMAL SYSTEM CONTAINING ACETYLSALICYLIC ACID FOR TREATMENT OF MIGRAINE” (US 2003/0008852 Al). Franke Hanshermann et al. used acetylsalicylic acid for treatment of migraine and other serotonin-dependent, platelet-mediated disorders with aid of a transdermal therapeutic system. These methods of inhalation and transdermal therapeutic system are not cost effective and user friendly. [0006] There is, therefore, a need for a cost-effective, user-friendly, and fast method to relieve pains. There is further a need for a pain-relief medicine to relieve headaches effectively.

SUMMARY OF THE DISCLOSURE

[0007] This summary is intended to provide an overview of the subject matter of this patent, and is not intended to identify essential elements or key elements of the subject matter, nor is it intended to be used to determine the scope of the claimed implementations. The proper scope of this patent may be ascertained from the claims set forth below in view of the detailed description below and the drawings.

[0008] According to one or more exemplary embodiments, the present disclosure is directed to a topical pain-relief medicine. In an exemplary embodiment, an exemplary topical painrelief medicine may include an aqueous mixture, Prednisolone powder, and Aspirin powder dissolved in a hydrophobic solvent. In an exemplary embodiment, an exemplary aqueous mixture may include Nortriptyline powder with a weight percent in a range of 0.1 wt. % to 0.6 wt. % to a total amount of an exemplary topical pain-relief medicine, Biperiden powder with a weight ratio in a range of 1 : 1 to 1 :60 (Biperiden powder: Nortriptyline powder), and water with a volume in a range of 0.5 mL to 30 mL in 100 g of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary Nortriptyline powder and an exemplary Biperiden powder may be dissolved in water. In an exemplary embodiment, Prednisolone powder may have a weight ratio in a range of 6:1 to 1:6 (Prednisolone powder: Nortriptyline powder). In an exemplary embodiment, Aspirin powder may have a weight ratio in a range of 1.6:1 to 60:1 (Aspirin powder: Nortriptyline powder). In an exemplary embodiment, an exemplary hydrophobic solvent may have a weight percent in a range of 85 wt. % to 99 wt. % in a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary aqueous mixture, an exemplary Prednisolone powder, and an exemplary Aspirin powder dissolved in an exemplary hydrophobic solvent may be mixed together to form a homogenous ointment or lotion. In an exemplary embodiment, an exemplary homogenous ointment or lotion may be topically administered on a body of a patient at least once a day.

[0009] According to one or more exemplary embodiments, the present disclosure is directed to a topical pain-relief medicine. In an exemplary embodiment, an exemplary pain-relief medicine may include an aqueous mixture, a steroid compound powder, and a nonsteroidal anti-inflammatory drug powder dissolved in a hydrophobic solvent. In an exemplary embodiment, an exemplary aqueous mixture may include a tricyclic antidepressant compound powder, an anticholinergic compound powder, and water. In an exemplary embodiment, an exemplary tricyclic antidepressant compound powder and an exemplary anticholinergic compound powder may be dissolved in water. In an exemplary embodiment, an exemplary aqueous mixture, an exemplary steroid compound powder, and an exemplary nonsteroidal antiinflammatory drug powder dissolved in an exemplary hydrophobic solvent may be mixed together to form a homogenous ointment or lotion.

[0010] In an exemplary embodiment, an exemplary tricyclic antidepressant compound may include at least one of Nortriptyline, Trimipramine, Amitriptyline, and combinations thereof. In an exemplary embodiment, an exemplary anticholinergic compound may include at least one of Trihexyphenidyl, Biperiden, Hyoscine, and combinations thereof. In an exemplary embodiment, an exemplary steroid compound may include at least one of Dexamethasone, Prednisolone, Methylprednisolone, and combinations thereof. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug may include at least one of Aspirin, Ibuprofene, Naproxen, and combinations thereof. In an exemplary embodiment, an exemplary hydrophobic solvent may include at least one of eucerin, cold cream, petroleum jelly, and combinations thereof.

[0011] In an exemplary embodiment, exemplary particles of each of an exemplary tricyclic antidepressant compound powder, an exemplary anticholinergic compound powder, steroid compound powder, and an exemplary nonsteroidal anti-inflammatory drug powder may include particles with an average particle size in a range of 100 nm to 170 pm.

[0012] In an exemplary embodiment, an exemplary topical pain-relief medicine may include tricyclic antidepressant compound powder with a weight ratio in a range of 1:5 to 1:500 (tricyclic antidepressant compound powder: nonsteroidal anti-inflammatory drug powder).

[0013] In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary steroid compound powder with a weight ratio in a range of 100: 1 to 1 :200 (steroid compound powder: tricyclic antidepressant compound powder).

[0014] In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary anticholinergic compound powder with a weight ratio in a range of 1:5 to 1:500 (anticholinergic compound powder: tricyclic antidepressant compound powder).

[0015] In an exemplary embodiment, an exemplary topical pain-relief medicine may include water with a volume in a range of 0.5 mL to 30 mL in 100 g of an exemplary topical pain-relief medicine. In an exemplary embodiment, water may include at least one of tap water, dextrose saline serum, distilled water, normal saline serum, and combinations thereof.

[0016] In an exemplary embodiment, an exemplary topical pain-relief medicine may be used for at least one of neuropathic pain, headache, muscle pain, joint pain, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may be topically administered to at last one of temporal region, frontal region, occipital region, and combinations thereof of a head of a patient for at least once a day.

[0017] According to one or more exemplary embodiments, the present disclosure is directed to a method for relieving headache. In an exemplary embodiment, an exemplary method may include producing a pain-relief medicine and topically administrating an exemplary pain-relief medicine to at last one of temporal region, frontal region, occipital region, and combinations thereof of a head of a patient at least once a day. In an exemplary embodiment, producing an exemplary pain-relief medicine may include forming a first mixture by dissolving at least one tricyclic antidepressant compound powder and at least one anticholinergic compound powder in water, forming a second mixture by mixing an exemplary first mixture and at least one steroid compound powder, forming a nonsteroidal anti-inflammatory drug solution by dissolving at least one nonsteroidal anti-inflammatory drug powder in at least one hydrophobic solvent, and forming a homogeneous ointment or lotion by mixing an exemplary second mixture with an exemplary nonsteroidal anti-inflammatory drug solution.

[0018] In an exemplary embodiment, an exemplary method may further include forming an exemplary at least one steroid compound powder by grinding at least one steroid compound to particles each with an average particle size in a range of 100 nm to 170 pm.

[0019] In an exemplary embodiment, an exemplary method may further include forming an exemplary at least one nonsteroidal anti-inflammatory drug powder by grinding at least one nonsteroidal anti-inflammatory drug to particles each with an average particle size in a range of 100 nm to 170 pm.

[0020] In an exemplary embodiment, an exemplary method may further include forming an exemplary at least one anticholinergic compound powder by grinding at least one anticholinergic compound to particles each with an average particle size in a range of 100 nm to 170 pm.

[0021] In an exemplary embodiment, an exemplary method may further include forming an exemplary at least one tricyclic antidepressant compound powder by grinding at least one tricyclic antidepressant compound to particles each with an average particle size in a range of 100 nm to 170 pm.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The drawing figures depict one or more implementations in accord with the present teachings, by way of example only, not by way of limitation. In the figures, like reference numerals refer to the same or similar elements.

[0023] FIG. 1 illustrates a flowchart of a method for relieving pain, consistent with one or more exemplary embodiments of the present disclosure.

[0024] FIG. 2 illustrates a flowchart of a method for producing a pain-relief medicine, consistent with one or more exemplary embodiments of the present disclosure.

DESCRIPTION OF EMBODIMENTS

[0025] In the following detailed description, numerous specific details are set forth by way of examples in order to provide a thorough understanding of the relevant teachings. However, it should be apparent that the present teachings may be practiced without such details. In other instances, well known methods, procedures, components, and/or circuitry have been described at a relatively high-level, without detail, in order to avoid unnecessarily obscuring aspects of the present teachings.

[0026] The novel features which are believed to be characteristic of the present disclosure, as to its structure, organization, use and method of operation, together with further objectives and advantages thereof, will be better understood from the following discussion. In the following detailed description, numerous specific details are set forth by way of examples in order to provide a thorough understanding of the relevant teachings. However, it should be apparent that the present teachings may be practiced without such details. In other instances, well known methods, procedures, components, and/or circuitry have been described at a relatively high- level, without detail, in order to avoid unnecessarily obscuring aspects of the present teachings. The following detailed description is presented to enable a person skilled in the art to make and use the methods and devices disclosed in exemplary embodiments of the present disclosure. For purposes of explanation, specific nomenclature is set forth to provide a thorough understanding of the present disclosure. However, it will be apparent to one skilled in the art that these specific details are not required to practice the disclosed exemplary embodiments. Descriptions of specific exemplary embodiments are provided only as representative examples. Various modifications to the exemplary implementations will be readily apparent to one skilled in the art, and the general principles defined herein may be applied to other implementations and applications without departing from the scope of the present disclosure. The present disclosure is not intended to be limited to the implementations shown, but is to be accorded the widest possible scope consistent with the principles and features disclosed herein.

[0027] The present disclosure is directed to exemplary embodiments of a topical pain-relief medicine and a method to produce and administer an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include active components to relieve pain. In an exemplary embodiment, exemplary active components may include a tricyclic antidepressant compound, an anticholinergic compound, a steroid compound, and a nonsteroidal anti-inflammatory drug. In an exemplary embodiment, an exemplary topical pain-relief medicine may include pain relievers and anti-inflammatory drugs. In an exemplary embodiment, an exemplary topical pain-relief medicine may include exemplary active components, water, and at least a hydrophobic solvent. In an exemplary embodiment, an exemplary pain-relief medicine may include an exemplary tricyclic antidepressant compound, an exemplary anticholinergic compound, an exemplary steroid compound, and an exemplary nonsteroidal anti-inflammatory drug.

[0028] In an exemplary embodiment, a tricyclic antidepressant compound powder may be produced by grinding an exemplary tricyclic antidepressant compound to an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary topical painrelief medicine may include an exemplary tricyclic antidepressant compound powder with a weight percent in a range of 0.2 wt. % to 10 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary tricyclic antidepressant compound powder with a weight ratio in a range of 1:5 to 1:500 (tricyclic antidepressant compound powder: nonsteroidal antiinflammatory drug powder). In an exemplary embodiment, an exemplary tricyclic antidepressant compound may include at least one of Nortriptyline, Trimipramine, Amitriptyline, and combinations thereof. In an exemplary embodiment an exemplary topical pain-relief medicine may include Nortriptyline powder with a weight percent in a range of 0.1 wt. % to 0.6 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include Nortriptyline powder with a weight ratio in a range of 6:1 to 1:6 (Prednisolone powder: Nortriptyline powder).

[0029] In an exemplary embodiment, an exemplary anticholinergic compound powder may be produced by grinding an exemplary anticholinergic compound to an average particle size in a range of 100 nm 170 pm. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary anticholinergic compound powder with a weight percent in a range of 0.004 wt. % to 0.4 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary anticholinergic compound powder with a weight ratio in a range of 1:5 to 1:500 (anticholinergic compound powder: tricyclic antidepressant compound powder). In an exemplary embodiment, an exemplary anticholinergic compound may include at least one of Trihexyphenidyl, Biperiden, Hyoscine, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary Biperiden powder with a weight ratio in a range of 1 : 1 to 1 :60 (Biperiden powder: Nortriptyline powder). [0030] In an exemplary embodiment, an exemplary tricyclic antidepressant compound powder and an exemplary anticholinergic compound powder may be dissolved in water. In an exemplary embodiment, an exemplary Nortriptyline powder and an exemplary Biperiden powder may be dissolved in water. In an exemplary embodiment, an exemplary topical painrelief medicine may include water with a weight percent in a range of 0.5 wt. % to 30 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary water may include at least one of tap water, dextrose saline serum, distilled water, normal saline serum, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may include 0.5 mL to 30 mL water in 100 g of an exemplary topical pain-relief medicine.

[0031] In an exemplary embodiment, a steroid compound powder may be produced by grinding an exemplary steroid compound to an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary steroid compound powder with a weight percent in a range of 0.01 wt. % to 2 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary steroid compound powder with a weight ratio in a range of 100:1 to 1:200 (steroid compound powder: tricyclic antidepressant compound powder). In an exemplary embodiment, an exemplary steroid compound may include at least one of Dexamethasone, Prednisolone, Methylprednisolone, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary Prednisolone powder with a weight ratio in a range of 6:1 to 1:6 (Prednisolone powder: Nortriptyline powder).

[0032] In an exemplary embodiment, a nonsteroidal anti-inflammatory drug powder may be produced by grinding an exemplary nonsteroidal anti-inflammatory drug to an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary topical painrelief medicine may include an exemplary nonsteroidal anti-inflammatory drug powder with a weight percent in a range of 0.2 wt. % to 10 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary nonsteroidal anti-inflammatory drug powder with a weight ratio in a range of 1:5 to 1:500 (tricyclic antidepressant compound powder: nonsteroidal antiinflammatory drug powder). In an exemplary embodiment, an exemplary nonsteroidal antiinflammatory drug may include at least one of Aspirin, Ibuprofene, Naproxen, and combinations thereof. In an exemplary embodiment, an exemplary pain-relief medicine may include Aspirin powder with a weight ratio in a range of 1.6:1 to 60:1 (Aspirin powder: Nortriptyline powder).

[0033] In an exemplary embodiment, an exemplary pain-relief medicine may include at least an organic solvent with a weight percent in a range of 85 wt. % to 99 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary at least a hydrophobic solvent may include at least one of eucerin, cold cream, petroleum jelly, and combinations thereof. In an exemplary embodiment, an exemplary nonsteroidal antiinflammatory drug powder may be dissolves in an exemplary at least a hydrophobic solvent. [0034] In an exemplary embodiment, an exemplary topical pain-relief medicine may include a mixture of an exemplary dissolved tricyclic antidepressant compound powder and an exemplary anticholinergic compound powder in water, an exemplary steroid compound powder, and an exemplary dissolved nonsteroidal anti-inflammatory drug powder in an exemplary at least a hydrophobic solvent. In an exemplary embodiment, an exemplary mixture may include one of a lotion or an ointment. In an exemplary embodiment, an exemplary painrelief medicine may be a homogenous lotion or a homogenous ointment.

[0035] In an exemplary embodiment, an exemplary topical pain-relief medicine may be used to relieve at least one of neuropathic pain, joint pains, muscle pain, headache, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may use exemplary active components to relive an exemplary at least one of neuropathic pain, joint pains, muscle pain, headache, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may be a lotion or an ointment. In an exemplary embodiment, an exemplary topical pain-relief medicine may include water (watery phase) and at least a hydrophobic solvent (oily phase). In an exemplary embodiment, as used herein “ointment” may refer to an oily substance with more than 80% oil that may be rubbed on a skin. As used herein “lotion” may refer to a substance having less than 80 % oil content. In an exemplary embodiment, an exemplary topical pain-relief medicine may be rubbed on a part or an organ of a body that may hurt. In an exemplary embodiment, an exemplary topical painrelief medicine may be administered at least once a day. In an exemplary embodiment, an exemplary topical pain-relief medicine may be rubbed topically on skin of a patient.

[0036] In an exemplary embodiment, an exemplary topical pain-relief medicine may be used to lessen or eliminate headaches such as chronic headaches. In an exemplary embodiment, an exemplary topical pain-relief medicine may be rubbed on at least temporal region, frontal region, occipital region, and combinations thereof of a head of a patient to relieve headaches. In an exemplary embodiment, an exemplary topical pain-relief medicine may be applied/administered topically on a skin of a patient above pathways where superficial nerves pass under an exemplary skin. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered topically on a head of a patient on pathways where superficial nerves pass under scalp. In an exemplary embodiment, exemplary superficial nerves may transfer pain signals to brain. In an exemplary embodiment, exemplary superficial nerves may form a network beneath scalp. In an exemplary embodiment, most of exemplary superficial nerves of head may be positioned in at least temporal region, frontal region, occipital region, and combinations thereof. In an exemplary embodiment, to lessen or eliminate pain, an exemplary topical pain-relief medicine may be administered topically on skin of head to relieve headache. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered topically on at least one of temporal region, frontal region, occipital region, and combinations thereof where exemplary superficial nerves may exist beneath exemplary regions of head.

[0037] Head may have a plurality of superficial nerves to transfer pain signals. An exemplary plurality of superficial nerves may include greater occipital nerve (GON), lesser (or small) occipital nerve (LON), and trigeminal nerve. An exemplary GON may be a superficial nerve that may supply sensation to scalp at top of head, over ears and over parotid glands. An exemplary GON is located at occipital and temporal regions of brain. An exemplary LON may be a cutaneous spinal nerve that may come from cervical spinal nerve. An exemplary LON may be located at occipital region of brain. An exemplary trigeminal nerve may be responsible to send sensations such as pain, touch, and temperature to brain. An exemplary trigeminal nerve may be located on frontal region of head.

[0038] Exemplary superficial nerves may be target points for healing pain in medical technologies such as surgery, acupuncture, traditional medicine, etc. In an exemplary embodiment, exemplary medical technologies may administer therapy where exemplary superficial nerves may pass. For example, an exemplary acupuncture method may inject needles on pathways where exemplary superficial nerves exist. An exemplary traditional therapy may massage part of a body where exemplary superficial nerves pass beneath exemplary parts of body. In an exemplary embodiment, exemplary superficial nerves may be target points for applying an exemplary topical pain-relief medicine on skin above exemplary superficial nerves. In an exemplary embodiment, to relieve headache, an exemplary scalp where superficial nerves pass may be a target point for administering an exemplary topical pain-relief medicine. In an exemplary embodiment, for effectiveness of an exemplary topical pain-relief medicine, a determined amount of an exemplary topical pain-relief medicine may be administered on skin. In an exemplary embodiment, an exemplary predetermined amount may be a sufficient amount of an exemplary topical pain-relief medicine to fully cover a thin layer on a target area. In an exemplary embodiment, an exemplary target area may be a pain region of a body. In an exemplary embodiment, exemplary superficial nerves may be responsible for transferring signals of pain to an exemplary pain region. In an exemplary embodiment, an exemplary topical pain-relief medicine may be applied once a day on a skin above pathway of exemplary superficial nerves.

[0039] FIG. 1 illustrates a flowchart of a method 100 for relieving pain, consistent with one or more exemplary embodiments of the present disclosure. In an exemplary embodiment, method 100 may include a step 102 of producing a pain-relief medicine and a step 104 of topically administrating the pain-relief medicine. In an exemplary embodiment, an exemplary produced pain-relief medicine may include a homogenous ointment or lotion. [0040] In further detail with respect to step 102, step 102 may include producing a pain-relief medicine. FIG. 2 illustrates a flowchart of a method 200 for producing an exemplary painrelief medicine, consistent with one or more exemplary embodiments of the present disclosure. In an exemplary embodiment, method 200 may include a step 202 of forming a first mixture by dissolving at least one tricyclic antidepressant compound powder and at least one anticholinergic compound powder in water, a step 204 of forming a second mixture by mixing the first mixture and at least one steroid compound powder, a step 206 of forming a nonsteroidal anti-inflammatory drug solution, and a step 208 of forming a homogeneous ointment or lotion by mixing the second mixture with the nonsteroidal anti-inflammatory drug solution. In an exemplary embodiment, to relieve pain, an exemplary topical pain-relief medicine may be produced and administered topically on skin. In an exemplary embodiment, an exemplary topical pain-relief medicine may be produced according to steps 202 to 208.

[0041] In further detail with respect to step 202, step 202 of forming a first mixture may include mixing at least one tricyclic antidepressant compound powder and at least one anticholinergic compound powder in water. In an exemplary embodiment, mixing an exemplary tricyclic antidepressant compound powder and an exemplary anticholinergic compound powder in water may be performed using a mixer with a rotational speed in a range of 20 rpm to 70 rpm. In an exemplary embodiment, mixing an exemplary tricyclic antidepressant compound powder and an exemplary anticholinergic compound powder in water may be performed for 1 minute to 20 minutes. In an exemplary embodiment, an exemplary first mixture may be heated at a temperature in a range of 20 °C to 75 °C. In an exemplary embodiment, an exemplary tricyclic antidepressant compound may be grinded using a grinding machine. In an exemplary embodiment, an exemplary anticholinergic compound may be grinded using a grinding machine. An exemplary tricyclic antidepressant compound may block reuptake of serotonin and norepinephrine in body. In an exemplary embodiment, an exemplary tricyclic antidepressant compound may be used to treat at least one of major depressive disorder, anxiety disorders, obsessive-compulsive disorder, social phobia, attention-deficit hyperactivity disorder, chronic neuropathic pain, fibromyalgia syndrome, menopausal symptoms, and combinations thereof. An exemplary anticholinergic compound may block action of a neurotransmitter called acetylcholine in body. In an exemplary embodiment, an exemplary anticholinergic compound may be used to treat overactive bladder to chronic obstructive pulmonary disorder. [0042] In an exemplary embodiment, an exemplary tricyclic antidepressant compound powder may include at least one of Nortriptyline, Trimipramine, Amitriptyline, a Nortriptyline derivative, a Trimipramine derivative, an Amitriptyline derivative, and combinations thereof. In an exemplary embodiment, an exemplary tricyclic antidepressant compound powder may have an average particle size of less than 170 pm. In an exemplary embodiment, an exemplary tricyclic antidepressant compound powder may have an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary tricyclic antidepressant compound powder may have a weight percent in a range of 0.2 wt. % to 2 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary tricyclic antidepressant compound powder with a weight ratio in a range of 1:5 to 1:500 (tricyclic antidepressant compound powder: nonsteroidal anti-inflammatory drug powder). In an exemplary embodiment an exemplary topical pain-relief medicine may include Nortriptyline powder with a weight percent in a range of 0.1 wt. % to 0.6 wt. % to a total amount of an exemplary topical pain relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include Nortriptyline powder with a weight ratio in a range of 6:1 to 1:6 (Prednisolone powder: Nortriptyline powder).

[0043] In an exemplary embodiment, an exemplary anticholinergic compound powder may have an average particle size of less than 170 pm. In an exemplary embodiment, an exemplary anticholinergic compound powder may have an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary anticholinergic compound powder may include a weight percent in a range of 0.004 wt. % to 0.4 wt. % to a total amount of an exemplary topical pain -relief medicine. In an exemplary embodiment, an exemplary anticholinergic compound powder and an exemplary tricyclic antidepressant compound powder may be dissolve in water. In an exemplary embodiment, an exemplary topical painrelief medicine may include an exemplary anticholinergic compound powder with a weight ratio in a range of 1:5 to 1:500 (anticholinergic compound powder: tricyclic antidepressant compound powder). In an exemplary embodiment, an exemplary anticholinergic compound powder may include at least one of Trihexyphenidyl, Biperiden, Hyoscine, a Trihexyphenidyl derivative, a Biperiden derivative, a Hyoscine derivative, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary Biperiden powder with a weight ratio in a range of 1 : 1 to 1 :60 (Biperiden powder: Nortriptyline powder).

[0044] In an exemplary embodiment, an exemplary water may include at least one of tap water, dextrose saline serum, distilled water, normal saline serum, and combinations thereof. In an exemplary embodiment, an exemplary water may include a weight percent in a range of 0.5 wt. % to 30 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include 0.5 mL to 30 mL water in 100 g of an exemplary topical pain-relief medicine.

[0045] In further detail with respect to step 204, step 204 of forming an exemplary second mixture may include mixing an exemplary first mixture produced in step 202 with at least one steroid compound powder. In an exemplary embodiment, mixing an exemplary first mixture with an exemplary at least one steroid compound powder may be performed in a mixer with a rotational speed in a range of 20 rpm to 70 rpm. In an exemplary embodiment, an exemplary first mixture and an exemplary at least one steroid compound powder may be mixed for 1 minute to 20 minutes. In an exemplary embodiment, an exemplary first mixture and an exemplary at least one steroid compound powder may be heated at a temperature in a range of 20 °C to 75 °C. In an exemplary embodiment, an exemplary steroid compound may be grinded using a grinding machine. An exemplary steroid compound may be an organic compound that may contain a characteristic arrangement of four cycloalkane rings that may be joined to each other. An exemplary steroid compound may be used to treat certain conditions, such as inflammation and hypogonadism.

[0046] In an exemplary embodiment, each particle of an exemplary steroid compound powder may have an average particle size of less than 170 pm. In an exemplary embodiment, an exemplary steroid compound powder may have an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary steroid compound powder may include a weight percent in a range of 0.01 wt. % to 2 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary steroid compound powder with a weight ratio in a range of 100: 1 to 1:200 (steroid compound powder: tricyclic antidepressant compound powder). In an exemplary embodiment, an exemplary steroid compound powder may include at least one of Dexamethasone, Prednisolone, Methylprednisolone, a Dexamethasone derivative, a Prednisolone derivative, a Methylprednisolone derivative, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary Prednisolone powder with a weight ratio in a range of 6:1 to 1:6 (Prednisolone powder: Nortriptyline powder).

[0047] In further detail with respect to step 206, step 206 of forming a nonsteroidal antiinflammatory drug solution may include dissolving a nonsteroidal anti-inflammatory drug powder in at least a hydrophobic solvent. In an exemplary embodiment, dissolving an exemplary nonsteroidal anti-inflammatory drug powder in an exemplary at least a hydrophobic solvent may include mixing an exemplary nonsteroidal anti-inflammatory drug powder with an exemplary at least a hydrophobic solvent. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug powder may be mixed with an exemplary at least a hydrophobic solvent in a mixer with a rotational speed in a range of 20 rpm to 70 rpm. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug powder may be mixed with an exemplary at least a hydrophobic solvent for a time period in a range of 1 minute to 20 minutes. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug powder and an exemplary at least a hydrophobic solvent may be heated at a temperature in a range of 20 °C to 75 °C. An exemplary nonsteroidal anti-inflammatory drug may be used to relieve pain, reduce inflammation, and bring down a high temperature.

[0048] In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug may be grinded using a grinding machine. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug may be grinded to form an exemplary nonsteroidal anti-inflammatory drug powder. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug powder may include an average particle size of less than 170 pm. In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug powder may have an average particle size in a range of 100 nm to 170 pm. In an exemplary embodiment, an exemplary nonsteroidal antiinflammatory drug may include a weight percent in a range of 0.2 wt. % to 10 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary hydrophobic solvent may include at least one of eucerin, cold cream, petroleum jelly, and combinations thereof. In an exemplary embodiment, an exemplary hydrophobic solvent may include a weight percent in a range of 85 wt. % to 99 wt. % to a total amount of an exemplary topical pain-relief medicine. In an exemplary embodiment, an exemplary topical pain-relief medicine may include an exemplary nonsteroidal anti-inflammatory drug powder with a weight ratio in a range of 1:5 to 1:500 (tricyclic antidepressant compound powder: nonsteroidal anti-inflammatory drug powder). In an exemplary embodiment, an exemplary nonsteroidal anti-inflammatory drug may include at least one of Aspirin, Ibuprofene, Naproxen, an Aspirin derivative, an Ibuprofene derivative, a Naproxen derivative, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may include Aspirin powder with a weight ratio in a range of 1.6:1 to 60:1 (Aspirin powder: Nortriptyline powder).

[0049] In further detail with respect to step 208, step 208 of forming a homogeneous ointment or lotion may include forming an exemplary homogeneous ointment or lotion by mixing an exemplary second mixture with an exemplary nonsteroidal anti-inflammatory drug solution. In an exemplary embodiment, an exemplary second mixture may be a water-based solution and an exemplary nonsteroidal anti-inflammatory drug solution may be an oil-based solution. In an exemplary embodiment, forming an exemplary homogeneous ointment or lotion may include mixing an exemplary second mixture with an exemplary nonsteroidal anti-inflammatory drug solution in a mixer with a rotational speed in a range of 20 rpm to 70 rpm. In an exemplary embodiment, an exemplary second mixture may be mixed with an exemplary nonsteroidal antiinflammatory drug solution for a time period in a range of 1 minute to 20 minutes. In an exemplary embodiment, an exemplary homogeneous ointment or lotion may be heated at a temperature in a range of 20 °C to 75 °C for a time period in a range of 1 minute to 20 minutes. [0050] Referring back to FIG. 1, step 104 of topically administrating an exemplary topical pain-relief medicine may include administering a predetermined amount of an exemplary topical pain-relief medicine on a part or organ of a body of a patient. In an exemplary embodiment, an exemplary topical pain-relief medicine may be used for relieving at least one of muscle pains, joint pains, neuropathic pain, headaches, and combinations thereof. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered on an organ or a part of a body that aches. In an exemplary embodiment, an exemplary topical painrelief medicine may be rubbed on an organ or part of a body that aches. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered on an exemplary organ or an exemplary part of a body that aches, for at least once a day. In an exemplary embodiment, administering an exemplary topical pain-relief medicine may include covering an exemplary organ or an exemplary part of body that aches with a thin layer of an exemplary topical pain-relief medicine. In an exemplary embodiment, administering an exemplary topical pain-relief medicine may include rubbing an exemplary topical pain-relief medicine on an exemplary organ or an exemplary part of body that aches for at least once a day.

[0051] In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered on a skin where superficial nerves may pass beneath an exemplary skin. In an exemplary embodiment, different medical technologies, for example, traditional medicine, acupuncture, and massage therapy may use skin covering exemplary superficial nerves as target points for treatments. In an exemplary embodiment, exemplary target points may be skin of a patient where exemplary superficial nerves may pass. An exemplary acupuncture may inject needles on pathways where superficial neural system of body may exist. In an exemplary embodiment, an exemplary surgical therapy may use surgical treatments on an exemplary superficial neural system to repair connections, disconnect problematic nerves, etc. In an exemplary embodiment, an exemplary massage therapy may use pathways of exemplary superficial neurons for applying pressure.

[0052] In an exemplary embodiment, an exemplary topical pain-relief medicine may be used for lessening or eliminating headaches. In an exemplary embodiment, an exemplary headache may include migraine. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered topically on a part of a head where there may be a passage of superficial nerves. In an exemplary embodiment, exemplary superficial nerves may include greater occipital nerve (GON), lesser (or small) occipital nerve (LON), and trigeminal nerve. An exemplary trigeminal nerve may be responsible to send sensations such as pain, touch, and temperature to brain. An exemplary trigeminal nerve may be located on frontal region of brain. An exemplary GON may be a nerve that supplies sensation to scalp at top of head, over ears and over parotid glands. An exemplary GON may be located at occipital and temporal regions of brain. An exemplary LON may be a cutaneous spinal nerve that may come from cervical spinal nerve. An exemplary LON may be located at occipital region of brain. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered topically over exemplary superficial nerves of a head. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered once a day topically on a skin on exemplary passages of exemplary superficial nerves. In an exemplary embodiment, an exemplary topical pain-relief medicine may be administered topically on a skin above exemplary passages of at least an exemplary greater occipital nerve (GON), an exemplary lesser (or small) occipital nerve (LON), an exemplary trigeminal nerve, and combinations thereof. [0053] Example 1: producing an ointment

[0054] For producing an ointment, method 100 may be used. To produce an exemplary ointment, 150 mg of a dry nortriptyline compound was grinded to 10 pm particles. Then, 20 mg of biperiden powder was prepared by grinding a biperiden compound. After grinding, two powders were mixed together for one minute. After mixing two powders, 5 mL of distilled water was added to an exemplary two powder mixture. Water and an exemplary two powder were mixed together at a temperature in a range of 20°C to 30 °C for 10 minutes to homogenized and dissolve an exemplary two powder in an exemplary distilled water. Then, 250 mg of dry prednisolone was grinded to a particle size of 10 pm at a temperature of 20°C to 30 °C. Then an exemplary prednisolone powder was added to 1.5 gr of Aspirin powder. An exemplary mixture was homogenized for 2 minutes. Then, an exemplary mixture of prednisolone powder and Aspirin powder was added to an exemplary mixture of Nortriptyline and Biperiden and distilled water. An exemplary mixture was stirred for 10 minutes and was placed in a quiet place for2 hours for complete dissolution process. An exemplary final mixture was combined with 50 gr cold cream (eucerin) and stirred for 30 minutes.

[0055] An exemplary final obtained ointment has a light color with almost neutral pH. An exemplary ointment may be maintained below 30 °C without freezing. An exemplary ointment may be used for chronic headaches. An exemplary ointment may be used topically three times on temporal, frontal and occipital regions which may be used by Iranian medicine massage therapy and acupuncture in treatment of headache.

[0056] For analyzing an exemplary produced ointment, Mann-Whitney U test and Wilcoxon signed-rank test were used. Mann-Whitney U test is a nonparametric test of null hypothesis that specifies higher probability of one criteria for one group in comparison to another group. Wilcoxon signed-rank test is a non-parametric statistical hypothesis test. Table 1 illustrates results of Mann-Whitney U test and Wilcoxon signed-rank test for one day of a group of patients with chronic headaches who used the produced ointment and a control group who suffer from chronic headaches but they did not use any treatments. An exemplary treated group used the treatments for 60 days. Results indicated that average hours a day of an exemplary treated group having headaches was 1.32+1.71 with an average of 1 hour but before the treatments it was 14.12+4.49 with an average of 15 hours. Results of Mann-Whitney U test showed that the average hours of having headaches in treated group was noticeably decreased (p<0.001) in comparison to an exemplary control group (p=0.87). [0057] Table 1. Results of Mann-Whitney U test and Wilcoxon signed-rank test on a treated group and a control group after 60 days of using the treatments.

[0058] Table 2. illustrates results of Mann-Whitney U test and Wilcoxon signed-rank test of a group of patients with chronic headaches who used an exemplary produced ointment and a control group who suffers from chronic headaches but they did not use any treatments for one month. Results show that average days of having headache in a month for an exemplary treated group was 1.94+2.42 day and for the control group was 25.73+5.59. Results show that after treatment with an exemplary produced pain-relief ointment, an average day of having headaches were noticeably decreased. According to Mann-Whitney U test these two groups were almost the same before treatments (p=0.55) but after the treatments they were noticeably different (p<0.001). Wilcoxon signed-rank test also showed that the average days of having headaches were noticeably decreased in an exemplary treated group after one month p<0.001. [0059] Table 2. Results of Mann-Whitney U test and Wilcoxon signed-rank test after one moth of using exemplary treatments on a treated group and a control group.

[0060] Table 3 illustrates results of intensity of headache using visual analog scale (VAS) criteria using Mann-Whitney U test and Wilcoxon signed-rank test of a group of patients with chronic headaches who used the produced ointment and a control group who suffers from chronic headaches but they did not use any treatments. For analyzing an intensity of headache, VAS criterion was used. Results show that the average intensity of headache in an exemplary treated group before exemplary treatments was 9.41+0.82 with an average of 10 and after exemplary treatments it was 1.23+1.07 with an average of 1. Results of Mann-Whitney U test showed that the intensity of the headache was noticeably lower for an exemplary treated group (p<0.001) than the intensity of the headache for an exemplary control group and an exemplary treated group before the treatments (p=0.72).

[0061] Table 3. Results of intensity of headache of a treated group and a control group using Mann-Whitney U test and Wilcoxon signed-rank test.

[0062] Industrial Applicability

[0063] The present disclosure may include a pain relief medicine in a form of an ointment or a lotion to eliminate pains. An exemplary pain -relief medicine may be produced by a simple method with known active components to relieve pains, for example, headaches. Due to simple process of production and administration, an exemplary pain-relief medicine may be produced and administered in hospitals and clinics. Furthermore, an exemplary pain-relief medicine may be used at home for relieving headache.

[0064] While the foregoing has described what are considered to be the best mode and/or other examples, it is understood that various modifications may be made therein and that the subject matter disclosed herein may be implemented in various forms and examples, and that the teachings may be applied in numerous applications, only some of which have been described herein. It is intended by the following claims to claim any and all applications, modifications and variations that fall within the true scope of the present teachings.

[0065] Unless otherwise stated, all measurements, values, ratings, positions, magnitudes, sizes, and other specifications that are set forth in this specification, including in the claims that follow, are approximate, not exact. They are intended to have a reasonable range that is consistent with the functions to which they relate and with what is customary in the art to which they pertain.

[0066] The scope of protection is limited solely by the claims that now follow. That scope is intended and should be interpreted to be as broad as is consistent with the ordinary meaning of the language that is used in the claims when interpreted in light of this specification and the prosecution history that follows and to encompass all structural and functional equivalents. Notwithstanding, none of the claims are intended to embrace subject matter that fails to satisfy the requirement of Sections 101, 102, or 103 of the Patent Act, nor should they be interpreted in such a way. Any unintended embracement of such subject matter is hereby disclaimed.

[0067] Except as stated immediately above, nothing that has been stated or illustrated is intended or should be interpreted to cause a dedication of any component, step, feature, object, benefit, advantage, or equivalent to the public, regardless of whether it is or is not recited in the claims.

[0068] It will be understood that the terms and expressions used herein have the ordinary meaning as is accorded to such terms and expressions with respect to their corresponding respective areas of inquiry and study except where specific meanings have otherwise been set forth herein. Relational terms such as first and second and the like may be used solely to distinguish one entity or action from another without necessarily requiring or implying any actual such relationship or order between such entities or actions. The terms “comprises,” “comprising,” or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. An element proceeded by “a” or “an” does not, without further constraints, preclude the existence of additional identical elements in the process, method, article, or apparatus that comprises the element.

[0069] The Abstract of the Disclosure is provided to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, it can be seen that various features are grouped together in various implementations. This is for purposes of streamlining the disclosure, and is not to be interpreted as reflecting an intention that the claimed implementations require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed implementation. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separately claimed subject matter.

[0070] While various implementations have been described, the description is intended to be exemplary, rather than limiting and it will be apparent to those of ordinary skill in the art that many more implementations and implementations are possible that are within the scope of the implementations. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any implementation may be used in combination with or substituted for any other feature or element in any other implementation unless specifically restricted. Therefore, it will be understood that any of the features shown and/or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the implementations are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.

Claims

22 What is claimed is:

1. A topical pain-relief medicine, comprising: an aqueous mixture, comprising:

Nortriptyline powder with a weight percent in a range of 0.1 wt. % to 0.6 wt.% to a total amount of the topical pain-relief medicine;

Biperiden powder with a weight ratio in a range of 1 : 1 to 1 :60 (Biperiden powder: Nortriptyline powder); and water with a volume in a range of 0.5 mL to 30 mL in 100 g of the topical pain-relief medicine, the Nortriptyline powder and the Biperiden powder being dissolved in water;

Prednisolone powder with a weight ratio in a range of 6:1 to 1:6 (Prednisolone powder: Nortriptyline powder); and

Aspirin powder dissolved in a hydrophobic solvent, the Aspirin powder having a weight ratio in a range of 1.6:1 to 60:1 (Aspirin powder: Nortriptyline powder), the hydrophobic solvent having a weight percent in a range of 85 wt. % to 99 wt. % a total amount of the topical pain-relief medicine, wherein the aqueous mixture, the Prednisolone powder, and the Aspirin powder dissolved in the hydrophobic solvent are mixed together to form a homogenous ointment or lotion, wherein the homogenous ointment or lotion is topically administered on a body of a patient at least once a day.

2. A topical pain-relief medicine, comprising: an aqueous mixture, comprising: a tricyclic antidepressant compound powder; an anticholinergic compound powder; and water, the tricyclic antidepressant compound powder and the anticholinergic compound powder being dissolved in water; a steroid compound powder; and a nonsteroidal anti-inflammatory drug powder dissolved in a hydrophobic solvent, wherein the aqueous mixture, the steroid compound powder, and the nonsteroidal anti-inflammatory drug powder dissolved in the hydrophobic solvent are mixed together to form a homogenous ointment or lotion.

3. The topical pain-relief medicine of claim 2, wherein the tricyclic antidepressant compound comprises at least one of Nortriptyline, Trimipramine, Amitriptyline, a Nortriptyline derivative, a Trimipramine derivative, an Amitriptyline derivative and combinations thereof.

4. The topical pain-relief medicine of claim 2, wherein the anticholinergic compound comprises at least one of Trihexyphenidyl, Biperiden, Hyoscine, a Trihexyphenidyl derivative, a Biperiden derivative, a Hyoscine derivative, and combinations thereof.

5. The topical pain-relief medicine of claim 2, wherein the steroid compound comprises at least one of Dexamethasone, Prednisolone, Methylprednisolone, a Dexamethasone derivative, a Prednisolone derivative, a Methylprednisolone derivative, and combinations thereof.

6. The topical pain-relief medicine of claim 2, wherein the nonsteroidal anti-inflammatory drug comprises at least one of Aspirin, Ibuprofene, Naproxen, an Aspirin derivative, an Ibuprofene derivative, a Naproxen derivative, and combinations thereof.

7. The topical pain-relief medicine of claim 2, wherein the hydrophobic solvent comprises at least one of eucerin, cold cream, petroleum jelly, and combinations thereof.

8. The topical pain-relief medicine of claim 2, wherein particles of each of the tricyclic antidepressant compound powder, the anticholinergic compound powder, steroid compound powder, and the nonsteroidal anti-inflammatory drug powder comprises particles with an average particle size in a range of 100 nm to 170 pm.

9. The topical pain-relief medicine of claim 2, wherein the topical pain-relief medicine comprises tricyclic antidepressant compound powder with a weight ratio in a range of 1:5 to 1:500 (tricyclic antidepressant compound powder: nonsteroidal anti-inflammatory drug powder).

10. The topical pain-relief medicine of claim 2, wherein the topical pain-relief medicine comprises the steroid compound powder with a weight ratio in a range of 100:1 to 1:200 (steroid compound powder: tricyclic antidepressant compound powder).

11. The topical pain-relief medicine of claim 2, wherein the topical pain-relief medicine comprises the anticholinergic compound powder with a weight ratio in a range of 1:5 to 1:500

(anticholinergic compound powder: tricyclic antidepressant compound powder). 25

12. The topical pain-relief medicine of claim 2, wherein the topical pain-relief medicine comprises water with a volume in a range of 0.5 mL to 30 mL in 100 g of the topical pain-relief medicine.

13. The topical pain-relief medicine of claim 2, wherein water comprises at least one of tap water, dextrose saline serum, distilled water, normal saline serum, and combinations thereof.

14. The topical pain-relief medicine of claim 2, wherein the topical pain-relief medicine is used for at least one of neuropathic pain, headache, muscle pain, joint pain, and combinations thereof.

15. The topical pain -relief medicine of claim 2, wherein the topical pain-relief medicine is topically administered to at last one of temporal region, frontal region, occipital region, and combinations thereof of a head of a patient for at least once a day.

16. A method for relieving headache, comprising: producing a pain-relief medicine, comprising: forming a first mixture by dissolving at least one tricyclic antidepressant compound powder and at least one anticholinergic compound powder in water; forming a second mixture by mixing the first mixture and at least one steroid compound powder; forming a nonsteroidal anti-inflammatory drug solution by dissolving at least one nonsteroidal anti-inflammatory drug powder in at least one hydrophobic solvent; and 26 forming a homogeneous ointment or lotion by mixing the second mixture with the nonsteroidal anti-inflammatory drug solution; and topically administrating the pain-relief medicine to at last one of temporal region, frontal region, occipital region, and combinations thereof of a head of a patient at least once a day.

17. The method of claim 16, further comprising forming the at least one steroid compound powder by grinding at least one steroid compound to particles each with an average particle size in a range of 100 nm to 170 pm.

18. The method of claim 16, further comprising forming the at least one nonsteroidal antiinflammatory drug powder by grinding at least one nonsteroidal anti-inflammatory drug to particles each with an average particle size in a range of 100 nm to 170 pm.

19. The method of claim 16, further comprising forming the at least one anticholinergic compound powder by grinding at least one anticholinergic compound to particles each with an average particle size in a range of 100 nm to 170 pm.

20. The method of claim 16, further comprising forming the at least one tricyclic antidepressant compound powder by grinding at least one tricyclic antidepressant compound to particles each with an average particle size in a range of 100 nm to 170 pm.